Commonwealth Diagnostics International,

Founded in 2015 in Salem, Mass., and operating out of its CLIA-certified laboratory and as an FDA-registered, ISO 13485-certified medical device manufacturer, Commonwealth Diagnostics International (CDI) helps providers identify and diagnose common sources of digestive distress and functional gastrointestinal ailments. CDI’s expansive portfolio of non-invasive at-home hydrogen and methane breath tests supports the diagnosis and treatment of Small Intestinal Bacterial Overgrowth (SIBO) and Intestinal Methanogen Overgrowth (IMO), as well as fructose malabsorption, lactose malabsorption, and sucrose malabsorption. Focused on patient-centric principles, CDI breath tests are easy-to-use, quick, and safe for patients and support meaningful GI health outcomes by helping steer each practitioner’s approach to dietary modification, homeopathic remedies, nutritional supplementation, immune support, high-quality probiotics, and additional testing.